---
title: "SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2025 Q1 EPS: USD 0.26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240062047.md"
datetime: "2025-05-13T20:56:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240062047.md)
  - [en](https://longbridge.com/en/news/240062047.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240062047.md)
---

# SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2025 Q1 EPS: USD 0.26

EPS: As of FY2025 Q1, the actual value is USD 0.26.

### Cash Position

Cash and cash equivalents were $6.2 million as of March 31, 2025, compared to $1.2 million as of December 31, 2024. This increase was primarily due to successful financing activities during the quarter, partially offset by operating expenses supporting clinical and preclinical development.

### Operating Expenses

Total operating expenses for Q1 2025 were $1.7 million, compared to $1.3 million in the same period of 2024. Research and development expenses decreased to $0.6 million for Q1 2025, compared to $1.0 million for Q1 2024, primarily due to decreased subcontractors and consultants expenses. General and administrative expenses increased to $1.1 million for Q1 2025, compared to $0.3 million for Q1 2024, mainly due to increased payroll expenses and higher professional services costs related to financing activities as a public company.

### Financial Expenses

Financial expenses, net for Q1 2025 were $0.1 million, compared to $0.2 million in Q1 2024, mainly due to reduced foreign exchange losses.

### Net Loss

Net loss for the first quarter of 2025 was $1.7 million, compared to $1.4 million for the first quarter of 2024. The increase was mainly due to higher general and administrative expenses related to being a public company, partially offset by decreased research and development expenses.

### Outlook / Guidance

Silexion Therapeutics plans to advance its pipeline toward clinical development, leveraging its enhanced financial position and strategic collaborations. The company aims to initiate clinical trials for its expanded dual-route development strategy for SIL204 in the first half of 2026. Additionally, Silexion has entered a strategic collaboration with Catalent to conduct formulation development and clinical manufacturing activities for SIL204.

### Related Stocks

- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [1 Unstoppable Stock to Buy Before It Joins Nvidia, Alphabet, Apple, and Microsoft in the $3 Trillion Club](https://longbridge.com/en/news/287021527.md)
- [Go Big or Go Home? Top Investor Weighs In On Cerebras Systems Stock](https://longbridge.com/en/news/287032625.md)
- [IonQ (IONQ) Is Building the Real Deal in Quantum but at a Steep Price](https://longbridge.com/en/news/287035438.md)
- [Goldman Sachs set to be named lead left underwriter for SpaceX IPO, source says](https://longbridge.com/en/news/286975906.md)
- [Market Chatter: Intel Urges PC Makers to Adopt Advanced CPUs Amid Supply Crunch](https://longbridge.com/en/news/286955059.md)